You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Unresectable breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Breast Cancer, Unresectable Breast Cancer Trial in Saint Louis (DiviTum® TKa assay, CDK4/6 + Endocrine therapy)

Not yet recruiting
  • Metastatic Breast Cancer
  • Unresectable Breast Cancer
  • DiviTum® TKa assay
  • CDK4/6 + Endocrine therapy
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 27, 2023

DESTINY Breast Respond HER2-low Europe

Not yet recruiting
  • Unresectable Breast Cancer
  • +2 more
  • Trastuzumab deruxtecan
  • (no location specified)
Jul 6, 2023

Breast Tumors Trial in La Jolla (Cirmtuzumab + Paclitaxel)

Active, not recruiting
  • Breast Neoplasms
  • Cirmtuzumab + Paclitaxel
  • La Jolla, California
    University of California, San Diego
May 16, 2022

Breast Cancer Trial (SHR-A1811 for injection ; capecitabine)

Not yet recruiting
  • Breast Cancer
  • SHR-A1811 for injection ; capecitabine
  • (no location specified)
May 4, 2023

Metastatic or Locally-advanced Unresectable Breast Cancer Trial in New York (BYL719, Letrozole, Exemestane)

Completed
  • Metastatic or Locally-advanced Unresectable Breast Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 1, 2022

Breast Cancer Trial (RO7247669, Pembrolizumab, Nab-Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 2, 2023

Patients Receiving T-DXd for Treatment of HER2+ Unresectable

Not yet recruiting
  • Breast Cancer
  • None (Observational Study)
  • (no location specified)
Oct 20, 2022

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage I Trial in Shanghai (FWD1802, palbocilib)

Recruiting
  • Metastatic Breast Cancer
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 26, 2023

Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 12, 2023

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023

Breast Cancer Trial (Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F

Not yet recruiting
  • Breast Cancer
  • Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
  • Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
  • (no location specified)
Feb 22, 2023

HER2-low in Unresectable and/or Metastatic Breast Cancer

Not yet recruiting
  • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
    • (no location specified)
    Nov 6, 2023

    Metastatic Triple-Negative Breast Cancer Trial in Charlotte (Trilaciclib, Pembrolizumab, Gemcitabine)

    Not yet recruiting
    • Metastatic Triple-Negative Breast Cancer
    • Charlotte, North Carolina
      Levine Cancer Institute
    Aug 31, 2023

    Patterns and Associated Outcomes in Patients of China With

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Electronic medical record and hospital information system or other available resources
    • Beijing, China
    • +6 more
    Mar 3, 2023

    Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

    Not yet recruiting
    • Anatomic Stage III Breast Cancer AJCC v8
    • +4 more
    • Biopsy
    • +5 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Feb 14, 2023

    PROVIDENCE - Real-world Study in HER2-positive Unresectable or

    Not yet recruiting
    • Breast Neoplasms
    • +2 more
      • (no location specified)
      Oct 7, 2022

      Breast Cancer Trial (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • (no location specified)
      Jul 10, 2023

      Breast Cancer Trial in Guangzhou (NanoKnife LEDC System)

      Completed
      • Breast Cancer
      • NanoKnife LEDC System
      • Guangzhou, Guangdong, China
        FUDA Cancer Hospital
      Sep 1, 2021

      Metastatic Breast Cancer, Unresectable Breast Cancer Trial in United States (Letrozole, Palbociclib, Onapristone ER)

      Recruiting
      • Metastatic Breast Cancer
      • Unresectable Breast Cancer
      • Basking Ridge, New Jersey
      • +6 more
      Sep 12, 2022

      Human Epidermal Growth Factor Receptor 2-Positive Unresectable

      Active, not recruiting
      • Metastatic Breast Cancer
      • Locally Advanced Breast Cancer
        • Athens, Greece
        • +1 more
        Jun 20, 2022

        HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Trial in

        Recruiting
        • HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
        • SHR-A1811
        • Pyrotinib in combination with Capecitabine.
        • Guangzhou, Guangdong, China
          Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
        Aug 8, 2022

        Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los

        Recruiting
        • Anatomic Stage IV Breast Cancer AJCC v8
        • +5 more
        • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
        • +3 more
        • Los Angeles, California
          USC/Norris Comprehensive Cancer Center
        Jan 31, 2023

        Breast Cancer, Solid Tumor Trial in Shanghai (BL-B01D1)

        Recruiting
        • Breast Cancer
        • Solid Tumor
        • Shanghai, Shanghai, China
          Fudan University Cancer Hospital
        Jul 20, 2022

        Malignant Tumor of Breast Trial in Japan (DS-8201a)

        Completed
        Has Results
        • Malignant Neoplasm of Breast
        • Yokohama, Kanagawa, Japan
        • +6 more
        Mar 17, 2022

        Breast Cancer Trial (Tucatinib, Eribulin, Trastuzumab)

        Not yet recruiting
        • Breast Cancer
        • (no location specified)
        Jul 12, 2022